Impaired Cholesterol-Uptake Capacity of HDL Might Promote Target-Lesion Revascularization by Inducing Neoatherosclerosis After Stent Implantation
Overview
Authors
Affiliations
Background We evaluated the importance of high-density lipoprotein (HDL) functionality for target-lesion revascularization in patients treated with coronary stents using a rapid cell-free assay system to evaluate the functional capacity of HDL to accept additional cholesterol (cholesterol-uptake capacity; CUC). Methods and Results From an optical coherence tomography (OCT) registry of patients treated with coronary stents, 207 patients were enrolled and their HDL was functionally evaluated by measuring the CUC. Follow-up OCT was performed (median duration, 24.5 months after stenting) to evaluate the presence of neoatherosclerosis. Clinical follow-up was performed to assess target-lesion revascularization for a median duration of 42.3 months after stent implantation. Neoatherosclerosis was identified in 37 patients (17.9%). Multivariate logistic regression analysis revealed that a decreased CUC was independently associated with neoatherosclerosis (odds ratio, 0.799; P<0.001). The CUC showed a significant inverse correlation with incidence of target-lesion revascularization (odds ratio, 0.887; P=0.003) and with lipid accumulation inside stents, suggesting that neoatherosclerosis contributes to the association between CUC and target-lesion revascularization. Conclusions Impaired HDL functionality, detected as decreased CUC, might lead to future stent failure by provoking atherogenic changes of the neointima within stents. Both quantitative and qualitative assessments of HDL might enable the improved prediction of clinical outcomes after stent implantation.
Meng H, Zhou X, Li L, Liu Y, Liu Y, Zhang Y Int J Gen Med. 2025; 18:1383-1391.
PMID: 40070681 PMC: 11895695. DOI: 10.2147/IJGM.S502386.
Otsuka T J Atheroscler Thromb. 2022; 29(9):1271-1272.
PMID: 35650109 PMC: 9444802. DOI: 10.5551/jat.ED208.
Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1.
Hooshdaran B, Pressly B, Alferiev I, Smith J, Zoltick P, Tschabrunn C Sci Rep. 2022; 12(1):5464.
PMID: 35361857 PMC: 8971450. DOI: 10.1038/s41598-022-09524-y.
Amano H, Kojima Y, Hirano S, Oka Y, Aikawa H, Matsumoto S Heart Vessels. 2022; 37(7):1097-1105.
PMID: 35031881 DOI: 10.1007/s00380-021-02010-x.
Xu T, Feng B, Zheng Z, Li L, Zeng W, Wang D BMC Cardiovasc Disord. 2021; 21(1):402.
PMID: 34418965 PMC: 8379726. DOI: 10.1186/s12872-021-02212-1.